Cargando…
SABRE: a multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis
AIM: Acute bronchiolitis is the commonest cause for hospitalisation in infancy. Supportive care remains the cornerstone of current management and no other therapy has been shown to influence the course of the disease. It has been suggested that adding nebulised hypertonic saline to usual care may sh...
Autores principales: | Everard, Mark L, Hind, Daniel, Ugonna, Kelechi, Freeman, Jennifer, Bradburn, Mike, Cooper, Cindy L, Cross, Elizabeth, Maguire, Chin, Cantrill, Hannah, Alexander, John, McNamara, Paul S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251206/ https://www.ncbi.nlm.nih.gov/pubmed/25389139 http://dx.doi.org/10.1136/thoraxjnl-2014-205953 |
Ejemplares similares
-
Nebulised 3% hypertonic saline versus 0.9% saline for treating patients hospitalised with acute bronchiolitis: protocol for a randomised, double-blind, multicentre trial
por: Szupieńko, Sara, et al.
Publicado: (2023) -
Hypertonic saline (HS) for acute bronchiolitis: Systematic review and meta-analysis
por: Maguire, Chin, et al.
Publicado: (2015) -
Asthma, atopy and lung function in young adults after hospitalisation for bronchiolitis in infancy: impact of virus and sex
por: Sørensen, Karen Galta, et al.
Publicado: (2022) -
Comparison of nebulised 3% hypertonic saline with ipratropium bromide in treatment of children with bronchiolitis: a randomized control trial
por: Naveed, Hina, et al.
Publicado: (2023) -
Retrospective observational study of the influence of the COVID-19 outbreak on infants’ hospitalisation for acute bronchiolitis
por: Berdah, Laura, et al.
Publicado: (2022)